BIOMAT Database Logo BIOMAT Database Logo

[Lymphocyte subpopulations in maintenance hemodialysis patients receiving recombinant human erythropoietin]. 1993

Y Kaneko, and Y Motomiya, and K Arai, and Y Kagebayashi, and H Okada, and K Sasaki, and T Yoneda, and K Yoshida, and S Ozono, and Y Hirao
Department of Urology, Nara Medical University, Japan.

The effect of recombinant human erythropoietin (rHuEPO) on the lymphocyte subpopulations of maintenance hemodialysis patients has been studied. Peripheral lymphocyte counts, lymphocyte subpopulations (Two color analysis) and PHA-induced proliferative response were measured before and after rHuEPO administration during 8 months in 22 stable hemodialysis patients (mean age 52 years, mean duration of dialysis 48 months). We could find a significant increase in the proportions of CD4+ Leu8- cells, HLA-DR+ cells, CD8+ HLA-DR+ cells, CD14+ HLA-DR+ cells and CD4+ Leu8-/CD8+ CD11b+ cells ratios after rHuEPO therapy. In addition, a significant decrease in the proportions of CD16+ CD57- cells and CD20+ cells could be found after rHuEPO therapy. These results suggest that rHuEPO administration to stable hemodialysis patients induces increases in lymphocytes categorized into helper subset groups and in activated T lymphocytes.

UI MeSH Term Description Entries
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004921 Erythropoietin Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.
D005260 Female Females
D005921 Glomerulonephritis Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY. Bright Disease,Kidney Scarring,Glomerulonephritides,Scarring, Kidney
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Y Kaneko, and Y Motomiya, and K Arai, and Y Kagebayashi, and H Okada, and K Sasaki, and T Yoneda, and K Yoshida, and S Ozono, and Y Hirao
Lymphocyte subsets and delayed cutaneous hypersensitivity in hemodialysis patients receiving recombinant human erythropoietin.
January 1988, Contributions to nephrology,
Y Kaneko, and Y Motomiya, and K Arai, and Y Kagebayashi, and H Okada, and K Sasaki, and T Yoneda, and K Yoshida, and S Ozono, and Y Hirao
Lymphocyte subpopulations in maintenance hemodialysis patients.
January 1978, Journal of dialysis,
Y Kaneko, and Y Motomiya, and K Arai, and Y Kagebayashi, and H Okada, and K Sasaki, and T Yoneda, and K Yoshida, and S Ozono, and Y Hirao
Lymphocyte subsets in hemodialysis patients treated with recombinant human erythropoietin.
July 1993, Journal of clinical immunology,
Y Kaneko, and Y Motomiya, and K Arai, and Y Kagebayashi, and H Okada, and K Sasaki, and T Yoneda, and K Yoshida, and S Ozono, and Y Hirao
Evaluation of platelet hyperfunction in hemodialysis patients receiving recombinant human erythropoietin.
January 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation,
Y Kaneko, and Y Motomiya, and K Arai, and Y Kagebayashi, and H Okada, and K Sasaki, and T Yoneda, and K Yoshida, and S Ozono, and Y Hirao
Human recombinant erythropoietin treatment in transfusion dependent anemic patients on maintenance hemodialysis.
February 1989, Clinical nephrology,
Y Kaneko, and Y Motomiya, and K Arai, and Y Kagebayashi, and H Okada, and K Sasaki, and T Yoneda, and K Yoshida, and S Ozono, and Y Hirao
Echocardiographic findings in patients on maintenance hemodialysis substituted with recombinant human erythropoietin.
January 1989, Clinical nephrology,
Y Kaneko, and Y Motomiya, and K Arai, and Y Kagebayashi, and H Okada, and K Sasaki, and T Yoneda, and K Yoshida, and S Ozono, and Y Hirao
Improvement of nutritional status in patients receiving maintenance hemodialysis after correction of renal anemia with recombinant human erythropoietin.
January 1998, Nephron,
Y Kaneko, and Y Motomiya, and K Arai, and Y Kagebayashi, and H Okada, and K Sasaki, and T Yoneda, and K Yoshida, and S Ozono, and Y Hirao
Effects of recombinant human erythropoietin on T lymphocyte subsets in hemodialysis patients.
January 1990, ASAIO transactions,
Y Kaneko, and Y Motomiya, and K Arai, and Y Kagebayashi, and H Okada, and K Sasaki, and T Yoneda, and K Yoshida, and S Ozono, and Y Hirao
Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin.
July 1997, Clinical nephrology,
Y Kaneko, and Y Motomiya, and K Arai, and Y Kagebayashi, and H Okada, and K Sasaki, and T Yoneda, and K Yoshida, and S Ozono, and Y Hirao
Plasma thrombopoietin level and platelet indices in hemodialysis patients receiving recombinant human erythropoietin.
June 2010, International journal of laboratory hematology,
Copied contents to your clipboard!